Walgreens Boots Alliance provides update on Rite Aid deal

Currently, the stock carries a price to earnings ratio of 13.85, a price to book ratio of 1.84, and a price to sales ratio of 0.48. Company shares were Reiterated by Deutsche Bank on Aug 30, 2016 to “Buy”, Firm has raised the Price Target to $ 94 from a previous price target of $93.Shares were Reiterated by FBR Capital on Jul 7, 2016 to “Mkt Perform” and Lowered the Price Target to $ 85 from a previous price target of $90.Walgreens Boots Alliance Inc was Resumed by BofA/Merrill to “Buy” on Jun 7, 2016. At present, 0 analysts recommended Selling these shares while 9 recommended Hold, according to FactSet data. The Hedge Fund company now holds 60,957 shares of WBA which is valued at $5,053,945. (NASDAQ:EA) has a consensus rating of 1.47. 0 analysts assign “Sell” rating for the stock. Investors will be eagerly eyeing the number the company reports compared to the earnings per share that brokers are predicting. (NASDAQ:WBA) tinted gains of +1.52% (+1.24 points) to US$82.88. Most recent session’s volume of 3.32 million shares lower than its average volume of 4.78 million shares. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand). (NASDAQ:WBA). According to First Call, the consensus price target for the company is $91.98. Presently, it has been ranked as “Buy” from 12 Financial Analysts. “Underperform” verdict was shared by 0 analyst and “Overweight” recommendation was issued by 9 analyst.

Walgreens Boots Alliance Inc has moved 0.50% above its 50-day simple moving average of $81.25 and went up 1.50% from its 200-day simple moving average of $81.06. EPS ratio considered by looking at last twelve month figures is 2.9. The institutional ownership stake in the corporation is 61.40% while the Beta value stands at 1.02.